127.09
Novartis Ag Adr stock is traded at $127.09, with a volume of 43,522.
It is down -0.87% in the last 24 hours and up +8.64% over the past month.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
See More
Previous Close:
$128.05
Open:
$127.29
24h Volume:
43,522
Relative Volume:
0.03
Market Cap:
$268.30B
Revenue:
$53.40B
Net Income/Loss:
$13.68B
P/E Ratio:
18.36
EPS:
6.9231
Net Cash Flow:
$16.89B
1W Performance:
-1.01%
1M Performance:
+8.64%
6M Performance:
+9.93%
1Y Performance:
+8.51%
Novartis Ag Adr Stock (NVS) Company Profile
Name
Novartis Ag Adr
Sector
Industry
Phone
-
Address
-
Compare NVS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NVS
Novartis Ag Adr
|
127.01 | 249.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
![]()
LLY
Lilly Eli Co
|
748.58 | 662.16B | 53.26B | 13.80B | -50.20M | 15.30 |
![]()
JNJ
Johnson Johnson
|
175.42 | 429.00B | 90.62B | 22.66B | 18.18B | 9.35 |
![]()
ABBV
Abbvie Inc
|
209.06 | 370.61B | 58.33B | 3.73B | 18.24B | 2.10 |
![]()
MRK
Merck Co Inc
|
84.02 | 210.04B | 63.43B | 16.42B | 14.72B | 6.49 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-08-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Feb-13-25 | Downgrade | UBS | Buy → Neutral |
Feb-12-25 | Initiated | Morgan Stanley | Underweight |
Feb-04-25 | Upgrade | Deutsche Bank | Hold → Buy |
Dec-04-24 | Downgrade | HSBC Securities | Hold → Reduce |
Sep-11-24 | Downgrade | BofA Securities | Buy → Neutral |
Sep-05-24 | Downgrade | Goldman | Buy → Neutral |
Sep-03-24 | Downgrade | Jefferies | Buy → Hold |
Jul-19-24 | Downgrade | Deutsche Bank | Buy → Hold |
May-30-24 | Initiated | Goldman | Buy |
Feb-23-24 | Initiated | BMO Capital Markets | Market Perform |
Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
Jan-16-24 | Resumed | UBS | Buy |
Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
Sep-25-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Apr-26-23 | Upgrade | Deutsche Bank | Hold → Buy |
Mar-27-23 | Upgrade | Deutsche Bank | Sell → Hold |
Jan-26-23 | Downgrade | Citigroup | Buy → Neutral |
Dec-05-22 | Upgrade | Stifel | Hold → Buy |
Sep-15-22 | Downgrade | Credit Suisse | Neutral → Underperform |
Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
May-09-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Jan-10-22 | Resumed | Citigroup | Buy |
Dec-14-21 | Downgrade | Redburn | Buy → Neutral |
Dec-06-21 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
Dec-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
Sep-20-21 | Downgrade | Deutsche Bank | Hold → Sell |
Mar-22-21 | Initiated | Bernstein | Mkt Perform |
Mar-10-21 | Downgrade | Argus | Buy → Hold |
Feb-01-21 | Downgrade | Cowen | Outperform → Market Perform |
Jan-15-21 | Initiated | Deutsche Bank | Buy |
Sep-29-20 | Initiated | Berenberg | Buy |
Sep-10-20 | Upgrade | UBS | Neutral → Buy |
Sep-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jun-15-20 | Upgrade | Citigroup | Neutral → Buy |
Mar-10-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Feb-25-20 | Downgrade | Guggenheim | Buy → Neutral |
Apr-25-19 | Upgrade | Guggenheim | Neutral → Buy |
Apr-25-19 | Upgrade | Liberum | Hold → Buy |
Apr-10-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jan-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
Dec-11-18 | Resumed | Jefferies | Buy |
Oct-09-18 | Initiated | Guggenheim | Neutral |
Sep-10-18 | Upgrade | BofA/Merrill | Underperform → Buy |
May-29-18 | Downgrade | HSBC Securities | Buy → Hold |
May-25-18 | Upgrade | Credit Suisse | Underperform → Neutral |
Jan-25-18 | Reiterated | Leerink Partners | Outperform |
Dec-06-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
Jul-26-17 | Upgrade | Morgan Stanley | Underweight → Overweight |
Jul-05-17 | Downgrade | Credit Suisse | Neutral → Underperform |
Mar-09-17 | Initiated | Liberum | Buy |
View All
Novartis Ag Adr Stock (NVS) Latest News
Global Industrial Biomanufacturing Market Report 2026-2036: Sustainability, Synthetic Biology, and Circular Economy Drive Growth - GlobeNewswire Inc.
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - sharewise.com
Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - Ariva
Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm - sharewise.com
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease - Novartis
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease - Ariva
What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum? - Morningstar
Sustainable dividends from European stocks poised to benefit from the tariff wars - The Globe and Mail
INCY's Q2 Earnings & Revenues Beat Estimates On Higher Product Sales - Barchart.com
NVS’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Novartis Holds a Strong Branded Drug Portfolio, Supporting Steady Long-Term Growth - Morningstar
Novartis Beats On Q2 Earnings And Sales, CFO Retires, Stock Down - Barchart.com
Novartis ADR earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
Will Key Drugs Maintain Momentum For Novartis In Q2 Earnings? - Barchart.com
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? - Yahoo Finance
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS) - Barchart.com
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study - TradingView
Incyte Gains 9.2% In Three Months: Buy, Hold Or Sell The Stock? - Barchart.com
Novartis completes acquisition of Regulus Therapeutics - Novartis
5 Large Drug Stocks That Are Poised To Ride On Sector Recovery - Barchart.com
NVO Stock Gains After Parvus Asset Management Builds Stake - Barchart.com
Novartis Ag Adr Stock (NVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):